论文部分内容阅读
在合成SIRPα蛋白(CV1单核细胞)和抗癌药物利妥昔单抗的双重打击下,小鼠体内的肿瘤在29天后被清除。为了避免被免疫系统破坏,癌细胞耍了一些小手段。当它们分裂形成肿瘤时,会避免让巨噬细胞察觉到,巨噬细胞是从事消灭死亡细胞和危险入侵者的免疫细胞。现在,许多癌症患者都在利用抗体药物进行治疗,这些抗体药物的部分作用是标识肿瘤细胞以便让巨噬细胞消灭它们。尽管这些药物可以延长患者的生命,但它们并不总是非常有效--部分原因在于癌细胞会通过给免疫细胞发送一个“别吃我”的信号进行反击。现
Tumors in mice were cleared after 29 days under double challenge with synthetic SIRPα protein (CV1 monocytes) and the anti-cancer drug rituximab. In order to avoid being destroyed by the immune system, cancer cells play a small means. When they divide to form tumors, they avoid being able to perceive macrophages, which are immune cells that kill dead cells and dangerous invaders. Nowadays, many cancer patients are treated with antibody drugs. Part of the function of these antibody drugs is to identify tumor cells in order for macrophages to eliminate them. Although these drugs can prolong the life of patients, they are not always effective - in part because cancer cells counterattack by sending an immune cell a “Do not eat me” signal. Now